Condition: Locally Advanced or Metastatic Solid Tumors · Sponsor: Avistone Biotechnology Co., Ltd.
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
This description comes directly from the study's public registry record.
Avistone Clinical Study Information Center · 8610 84148921 · information.center@avistonebio.com
Always discuss trial participation with your own doctor first.
| University of California, San Diego | San Diego, California, United States | Recruiting |
| Sarah Cannon Research Institute | Denver, Colorado, United States | Recruiting |
| Advent Health | Orlando, Florida, United States | Recruiting |
| Henry Ford Health Cancer | Detroit, Michigan, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| The University of Texas - MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Oncology, Virginia | Fairfax, Virginia, United States | Recruiting |
| Swedish Cancer Institute | Seattle, Washington, United States | Recruiting |
| BC Cancer Vancouver Centre | Vancouver, British Columbia, Canada | Recruiting |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
| Beijing Chest Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06307795